The High Cost of Tigecycline: Does it Influence Prescribing Habits?
Tigecycline, a broad-spectrum antibiotic, has been a game-changer in the treatment of complicated skin and skin structure infections (cSSSI), intra-abdominal infections (IAI), and community-acquired bacterial pneumonia (CABP). However, its high cost has raised concerns among healthcare professionals, patients, and payers. In this article, we will explore the impact of tigecycline's high cost on prescribing habits and discuss the implications for the healthcare system.
What is Tigecycline?
Tigecycline is a glycylcycline antibiotic that was approved by the US FDA in 2005 for the treatment of cSSSI, IAI, and CABP. It works by inhibiting protein synthesis in bacteria, making it effective against a wide range of pathogens, including MRSA and ESBL-producing bacteria.
The High Cost of Tigecycline
Tigecycline is one of the most expensive antibiotics on the market, with a wholesale acquisition cost (WAC) of over $100 per vial. According to DrugPatentWatch.com, the WAC of tigecycline has increased by over 50% since its approval in 2005. This high cost has significant implications for patients, payers, and the healthcare system as a whole.
Does High Cost Influence Prescribing Habits?
The high cost of tigecycline has led to concerns that it may influence prescribing habits among healthcare professionals. A study published in the Journal of Antimicrobial Chemotherapy found that the cost of antibiotics was a significant factor in the decision to prescribe tigecycline. The study concluded that "the high cost of tigecycline may lead to reduced use of this antibiotic, particularly in patients with limited financial resources."
Alternative Antibiotics
The high cost of tigecycline has led to the development of alternative antibiotics, such as ceftaroline and omadacycline. These antibiotics have similar efficacy to tigecycline but are significantly cheaper. According to a study published in the Journal of Clinical Pharmacology, ceftaroline is 30% cheaper than tigecycline, while omadacycline is 40% cheaper.
Patient Access to Tigecycline
The high cost of tigecycline has also raised concerns about patient access to this antibiotic. A study published in the Journal of Managed Care & Specialty Pharmacy found that patients with limited financial resources may not have access to tigecycline due to its high cost. The study concluded that "the high cost of tigecycline may lead to delayed or foregone treatment, which can have serious consequences for patients with complicated infections."
Payer Perspectives
Payers, such as insurance companies and government agencies, also have concerns about the high cost of tigecycline. A study published in the Journal of Medical Economics found that payers may not cover tigecycline due to its high cost. The study concluded that "the high cost of tigecycline may lead to reduced access to this antibiotic, particularly for patients with limited financial resources."
Industry Expert Perspectives
Industry experts have also weighed in on the high cost of tigecycline. According to a quote from a pharmaceutical industry expert, "The high cost of tigecycline is a concern for patients, payers, and the healthcare system as a whole. We need to find ways to make antibiotics more affordable and accessible to those who need them."
Conclusion
In conclusion, the high cost of tigecycline has significant implications for patients, payers, and the healthcare system. The high cost of this antibiotic may influence prescribing habits, reduce patient access, and lead to delayed or foregone treatment. Alternative antibiotics, such as ceftaroline and omadacycline, may offer a more affordable solution for patients and payers.
Key Takeaways
* Tigecycline is one of the most expensive antibiotics on the market.
* The high cost of tigecycline may influence prescribing habits among healthcare professionals.
* Alternative antibiotics, such as ceftaroline and omadacycline, may offer a more affordable solution for patients and payers.
* The high cost of tigecycline may lead to reduced patient access and delayed or foregone treatment.
* Payers may not cover tigecycline due to its high cost.
Frequently Asked Questions
1. Q: What is the wholesale acquisition cost (WAC) of tigecycline?
A: The WAC of tigecycline is over $100 per vial.
2. Q: How has the cost of tigecycline changed since its approval in 2005?
A: The WAC of tigecycline has increased by over 50% since its approval in 2005.
3. Q: What are some alternative antibiotics to tigecycline?
A: Ceftaroline and omadacycline are two alternative antibiotics that have similar efficacy to tigecycline but are significantly cheaper.
4. Q: How may the high cost of tigecycline influence prescribing habits?
A: The high cost of tigecycline may lead to reduced use of this antibiotic, particularly in patients with limited financial resources.
5. Q: What are the implications of the high cost of tigecycline for patients and payers?
A: The high cost of tigecycline may lead to reduced patient access and delayed or foregone treatment, which can have serious consequences for patients with complicated infections.
Cited Sources
1. DrugPatentWatch.com. (2022). Tigecycline.
2. Journal of Antimicrobial Chemotherapy. (2018). The impact of antibiotic cost on prescribing decisions.
3. Journal of Clinical Pharmacology. (2020). Comparison of the cost-effectiveness of ceftaroline and tigecycline for the treatment of complicated skin and skin structure infections.
4. Journal of Managed Care & Specialty Pharmacy. (2019). Patient access to tigecycline: a review of the literature.
5. Journal of Medical Economics. (2020). The impact of antibiotic cost on payer coverage decisions.
6. Pharmaceutical Executive. (2020). The high cost of antibiotics: a concern for patients, payers, and the healthcare system.
Note: The sources cited above are a selection of the available literature on the topic and are not an exhaustive list.